David P Dearnaley

Summary

Affiliation: Institute of Cancer Research
Country: UK

Publications

  1. doi request reprint Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial
    David Dearnaley
    Royal Marsden NHS Foundation Trust, London, UK
    Lancet Oncol 13:43-54. 2012
  2. pmc Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects
    D P Dearnaley
    Academic Department of Radiotherapy and Oncology, Institute of Cancer Research, Sutton, Surrey SM2 5PT, UK
    Br J Cancer 92:488-98. 2005
  3. ncbi request reprint The early toxicity of escalated versus standard dose conformal radiotherapy with neo-adjuvant androgen suppression for patients with localised prostate cancer: results from the MRC RT01 trial (ISRCTN47772397)
    David P Dearnaley
    Institute of Cancer Research and Royal Marsden Hospitals, Sutton, UK
    Radiother Oncol 83:31-41. 2007
  4. pmc Adjuvant bleomycin, vincristine and cisplatin (BOP) for high-risk stage I non-seminomatous germ cell tumours: a prospective trial (MRC TE17)
    D P Dearnaley
    Academic Radiotherapy, Institute of Cancer Research and Royal Marsden Hospital, Sutton, Surrey SM2 5PT, UK
    Br J Cancer 92:2107-13. 2005
  5. ncbi request reprint Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial
    David P Dearnaley
    The Institute of Cancer Research, London, UK The Royal Marsden NHS Foundation Trust, London and Sutton, UK
    Lancet Oncol 15:464-73. 2014
  6. ncbi request reprint Assessing correlations between the spatial distribution of the dose to the rectal wall and late rectal toxicity after prostate radiotherapy: an analysis of data from the MRC RT01 trial (ISRCTN 47772397)
    Florian Buettner
    Joint Department of Physics, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK
    Phys Med Biol 54:6535-48. 2009
  7. pmc Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials
    David P Dearnaley
    Royal Marsden Foundation Trust and Institute of Cancer Research, Sutton, Surrey, UK
    Lancet Oncol 10:872-6. 2009
  8. ncbi request reprint Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial
    David P Dearnaley
    Institute of Cancer Research and Royal Marsden Hospitals, Sutton and London, UK
    Lancet Oncol 8:475-87. 2007
  9. ncbi request reprint A versatile phantom for quality assurance in the UK Medical Research Council (MRC) RT01 trial (ISRCTN47772397) in conformal radiotherapy for prostate cancer
    A Rollo Moore
    Medical Physics, Royal Marsden NHS Foundation Trust, London, UK
    Radiother Oncol 80:82-5. 2006
  10. ncbi request reprint Evaluating the relationship between erectile dysfunction and dose received by the penile bulb: using data from a randomised controlled trial of conformal radiotherapy in prostate cancer (MRC RT01, ISRCTN47772397)
    Stephen A Mangar
    Academic Department of Radiotherapy and Oncology, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton, Surrey, UK
    Radiother Oncol 80:355-62. 2006

Detail Information

Publications118 found, 100 shown here

  1. doi request reprint Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial
    David Dearnaley
    Royal Marsden NHS Foundation Trust, London, UK
    Lancet Oncol 13:43-54. 2012
    ..We present a pre-planned preliminary safety analysis of side-effects in stages 1 and 2 of a randomised trial comparing standard and hypofractionated radiotherapy...
  2. pmc Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects
    D P Dearnaley
    Academic Department of Radiotherapy and Oncology, Institute of Cancer Research, Sutton, Surrey SM2 5PT, UK
    Br J Cancer 92:488-98. 2005
    ..Data from this randomised pilot study informed the Data Monitoring Committee of the Medical Research Council RT 01 Trial and the two studies will be combined in subsequent meta-analysis...
  3. ncbi request reprint The early toxicity of escalated versus standard dose conformal radiotherapy with neo-adjuvant androgen suppression for patients with localised prostate cancer: results from the MRC RT01 trial (ISRCTN47772397)
    David P Dearnaley
    Institute of Cancer Research and Royal Marsden Hospitals, Sutton, UK
    Radiother Oncol 83:31-41. 2007
    ..Conformal radiotherapy (CFRT) raises the possibility that radiotherapy doses can be increased and long-term efficacy outcomes improved, with safety an important consideration...
  4. pmc Adjuvant bleomycin, vincristine and cisplatin (BOP) for high-risk stage I non-seminomatous germ cell tumours: a prospective trial (MRC TE17)
    D P Dearnaley
    Academic Radiotherapy, Institute of Cancer Research and Royal Marsden Hospital, Sutton, Surrey SM2 5PT, UK
    Br J Cancer 92:2107-13. 2005
    ..There are no clearcut advantages to 2 x BOP over 2 x BEP, except for patients who wish to maximise the chance of avoiding significant alopecia...
  5. ncbi request reprint Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial
    David P Dearnaley
    The Institute of Cancer Research, London, UK The Royal Marsden NHS Foundation Trust, London and Sutton, UK
    Lancet Oncol 15:464-73. 2014
    ..Based on the sample size calculation, we planned to analyse overall survival when 190 deaths occurred; this target has now been reached, after a median 10 years of follow-up...
  6. ncbi request reprint Assessing correlations between the spatial distribution of the dose to the rectal wall and late rectal toxicity after prostate radiotherapy: an analysis of data from the MRC RT01 trial (ISRCTN 47772397)
    Florian Buettner
    Joint Department of Physics, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK
    Phys Med Biol 54:6535-48. 2009
    ..Due to these significant correlations, it is desirable to use shape-based tools in order to assess the quality of a dose distribution...
  7. pmc Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials
    David P Dearnaley
    Royal Marsden Foundation Trust and Institute of Cancer Research, Sutton, Surrey, UK
    Lancet Oncol 10:872-6. 2009
    ..We report the final analyses of long-term survival data with additional follow-up in both trials...
  8. ncbi request reprint Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial
    David P Dearnaley
    Institute of Cancer Research and Royal Marsden Hospitals, Sutton and London, UK
    Lancet Oncol 8:475-87. 2007
    ..We aimed to present the first analyses of effectiveness from the MRC RT01 randomised controlled trial...
  9. ncbi request reprint A versatile phantom for quality assurance in the UK Medical Research Council (MRC) RT01 trial (ISRCTN47772397) in conformal radiotherapy for prostate cancer
    A Rollo Moore
    Medical Physics, Royal Marsden NHS Foundation Trust, London, UK
    Radiother Oncol 80:82-5. 2006
    ..The design provides a representative but reproducible system for QA in the prostate radiotherapy process, from CT scan to treatment. Setup errors are not eliminated, but minimised and estimated...
  10. ncbi request reprint Evaluating the relationship between erectile dysfunction and dose received by the penile bulb: using data from a randomised controlled trial of conformal radiotherapy in prostate cancer (MRC RT01, ISRCTN47772397)
    Stephen A Mangar
    Academic Department of Radiotherapy and Oncology, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton, Surrey, UK
    Radiother Oncol 80:355-62. 2006
    ..To evaluate the relationship between erectile function and the radiation dose to the penile bulb and other proximal penile structures in men receiving conformal radiotherapy (CFRT) for prostate cancer (PCa)...
  11. pmc Identification of new genetic risk factors for prostate cancer
    Michelle Guy
    Section of Cancer Genetics, The Institute of Cancer Research, Sutton, Surrey, UK
    Asian J Androl 11:49-55. 2009
    ..Follow-up validation studies, as well as studies to explore the psychological implications of genetic profile testing, will be vital prior to roll out into healthcare...
  12. doi request reprint A comparison of dose-volume constraints derived using peak and longitudinal definitions of late rectal toxicity
    Sarah L Gulliford
    Joint Department of Physics, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, UK
    Radiother Oncol 94:241-7. 2010
    ..An alternative definition (integrated longitudinal toxicity (ILT)) is proposed which takes into account both the severity and the duration of the complication...
  13. ncbi request reprint Efficacy of low-dose dexamethasone in castration-refractory prostate cancer
    Ramachandran Venkitaraman
    Academic Urology Unit, Royal Marsden Hospital, Sutton, Surrey, UK
    BJU Int 101:440-3. 2008
    ....
  14. pmc Issues in applying multi-arm multi-stage methodology to a clinical trial in prostate cancer: the MRC STAMPEDE trial
    Matthew R Sydes
    MRC Clinical Trials Unit, London, UK
    Trials 10:39. 2009
    ..The MAMS design will potentially facilitate evaluation and testing of new therapies in this and other diseases...
  15. ncbi request reprint Treating stage I nonseminomatous germ cell tumours with a single cycle of chemotherapy
    Duncan C Gilbert
    Academic Unit of Radiotherapy and Oncology, Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK
    BJU Int 98:67-9. 2006
    ..To estimate the rate of relapse in men with stage I nonseminomatous germ cell tumours (NSGCT) of the testis treated with one cycle of chemotherapy instead of the usual two cycles...
  16. pmc Flexible trial design in practice - stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial
    Matthew R Sydes
    MRC Clinical Trials Unit, London, UK
    Trials 13:168. 2012
    ..We describe methodological and practical issues arising with (1) stopping recruitment to research arms following a pre-planned intermediate analysis and (2) adding a new research arm during the trial...
  17. doi request reprint The dose-response of the anal sphincter region--an analysis of data from the MRC RT01 trial
    Florian Buettner
    Joint Department of Physics, Institute of Cancer Research, Surrey, UK
    Radiother Oncol 103:347-52. 2012
    ..In this study correlations between the 3D dose distribution to the anal-sphincter region and radiation-induced side-effects were quantified...
  18. doi request reprint Parameters for the Lyman Kutcher Burman (LKB) model of Normal Tissue Complication Probability (NTCP) for specific rectal complications observed in clinical practise
    Sarah L Gulliford
    Joint Department of Physics, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, UK
    Radiother Oncol 102:347-51. 2012
    ..The Normal Tissue Complication Probability (NTCP) for rectum is usually defined for late rectal bleeding. This study calculates NTCP parameter values for additional rectal toxicity endpoints observed in clinical practise...
  19. doi request reprint Clinical implications of introducing a new PSA assay
    Ramachandran Venkitaraman
    Academic Unit of Radiotherapy and Oncology, Institute of Cancer Research, Downs Road, Sutton, Surrey SM2 5PT, UK
    Int Urol Nephrol 40:657-61. 2008
    ..The availability of two assays in the same laboratory provided an opportunity to audit the clinical implications of the interassay variation in PSA levels...
  20. pmc Identification of seven new prostate cancer susceptibility loci through a genome-wide association study
    Rosalind A Eeles
    The Institute of Cancer Research, Sutton, Surrey, UK
    Nat Genet 41:1116-21. 2009
    ..In addition to replicating previous associations, we identified seven new prostate cancer susceptibility loci on chromosomes 2, 4, 8, 11 and 22 (with P = 1.6 x 10(-8) to P = 2.7 x 10(-33))...
  21. doi request reprint Stereotactic body radiotherapy for oligometastases
    Alison C Tree
    Royal Marsden NHS Foundation Trust, London, UK
    Lancet Oncol 14:e28-37. 2013
    ..However, to test whether SBRT really does improve progression-free survival, randomised trials will be essential...
  22. doi request reprint Can diet combined with treatment scheduling achieve consistency of rectal filling in patients receiving radiotherapy to the prostate?
    Helen A McNair
    Department of Radiotherapy, Royal Marsden NHS Foundation Trust and Institute of Cancer Research, Sutton, UK
    Radiother Oncol 101:471-8. 2011
    ..This pilot study investigates whether an individualized fluid and fibre prescription combined with a constant treatment can improve rectal filling consistency during radiotherapy...
  23. ncbi request reprint Outcome of early detection and radiotherapy for occult spinal cord compression
    Ramachandran Venkitaraman
    Academic Urology Unit, Royal Marsden Hospital, Downs Road, Sutton, Surrey, UK
    Radiother Oncol 85:469-72. 2007
    ..Thus MRI surveillance for SCC may be important for prostate cancer patients with bone metastases...
  24. pmc Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study
    Zsofia Kote-Jarai
    The Institute of Cancer Research, Sutton, Surrey, UK
    Nat Genet 43:785-91. 2011
    ..7 × 10(-24)). We also identified a SNP in TERT more strongly associated with PrCa than that previously reported. More than 40 PrCa susceptibility loci, explaining ∼25% of the familial risk in this disease, have now been identified...
  25. ncbi request reprint Reduction of small and large bowel irradiation using an optimized intensity-modulated pelvic radiotherapy technique in patients with prostate cancer
    C M Nutting
    Academic Department of Radiotherapy, Institute of Cancer Research and the Royal Marsden NHS Trust, Sutton, Surrey, UK
    Int J Radiat Oncol Biol Phys 48:649-56. 2000
    ..To investigate the role of intensity-modulated radiation therapy (IMRT) to irradiate the prostate gland and pelvic lymph nodes while sparing critical pelvic organs, and to optimize the number of beams required...
  26. ncbi request reprint Implementing the UK Medical Research Council (MRC) RT01 trial (ISRCTN 47772397): methods and practicalities of a randomised controlled trial of conformal radiotherapy in men with localised prostate cancer
    Matthew R Sydes
    Cancer Division, MRC Clinical Trials Unit, London, UK
    Radiother Oncol 72:199-211. 2004
    ..Radiotherapy is the most frequently used treatment for men with localised prostate cancer. Conformal radiotherapy (CFRT) is a relatively new development. MRC RT01 was set-up to explore optimum CFRT dose...
  27. doi request reprint Evaluating the efficacy of statins and ACE-inhibitors in reducing gastrointestinal toxicity in patients receiving radiotherapy for pelvic malignancies
    Linda J Wedlake
    Department of Nutrition and Dietetics, The Royal Marsden NHS Foundation Trust, London, UK
    Eur J Cancer 48:2117-24. 2012
    ..Animal data suggest that statins and ACE inhibitors (ACEi) may protect against normal tissue injury. Their efficacy in humans has not been reported...
  28. ncbi request reprint Intensity Modulated Radiotherapy (IMRT) in locally advanced thyroid cancer: acute toxicity results of a phase I study
    Teresa Guerrero Urbano
    Head and Neck Unit, Royal Marsden Hospital, London, UK
    Radiother Oncol 85:58-63. 2007
    ..This phase 1 study was designed to determine the toxicity of accelerated fractionation IMRT in locally advanced thyroid cancer...
  29. ncbi request reprint Variability of bladder filling in patients receiving radical radiotherapy to the prostate
    Una M O'Doherty
    Radiotherapy Department, Royal Marsden NHS Foundation Trust, Sutton, UK
    Radiother Oncol 79:335-40. 2006
    ..This study investigated patients' ability to consistently maintain a full bladder throughout planning and treatment before (Study 1) and after (Study 2) the introduction of a patient information sheet...
  30. doi request reprint A study of diffusion-weighted magnetic resonance imaging in men with untreated localised prostate cancer on active surveillance
    Nicholas J van As
    Academic Unit of Radiotherapy and Oncology, Department of Radiology, Royal Marsden NHS Foundation Trust and Institute of Cancer Research, Sutton, Surrey, UK
    Eur Urol 56:981-7. 2009
    ..Markers that predict the behaviour of localised prostate cancer are needed to identify patients that require treatment...
  31. ncbi request reprint Late recurrence in 1263 men with testicular germ cell tumors. Multivariate analysis of risk factors and implications for management
    Mehdi Shahidi
    Academic Department of Radiotherapy and Oncology, The Royal Marsden NHS Trust, Institute of Cancer Research, Downs Road, Sutton, Surrey SM2 5PT, United Kingdom
    Cancer 95:520-30. 2002
    ..The time-course of recurrence has implications for the duration of follow-up. This study was undertaken to assess the risk and time-course of recurrence and to identify patients at higher risk of late recurrence...
  32. ncbi request reprint The quality of life of men with locally advanced prostate cancer during neoadjuvant hormone therapy: data from the Medical Research Council RT01 trial (ISRCTN 47772397)
    Richard J Stephens
    Cancer Group, MRC Clinical Trials Unit, London, UK
    BJU Int 99:301-10. 2007
    ....
  33. ncbi request reprint Assessing intra-fractional bladder motion using cine-MRI as initial methodology for Predictive Organ Localization (POLO) in radiotherapy for bladder cancer
    Stephen A Mangar
    Department of Radiotherapy, Hammersmith Hospital NHS Trust, London, UK
    Radiother Oncol 85:207-14. 2007
    ..To assess the feasibility of using cine-MR to study intra-fractional time-volume and volume-deformity patterns of the bladder during radiotherapy as initial methodology for Predictive Organ Localization (POLO)...
  34. ncbi request reprint A comparison of forward and inverse planned conformal, multi segment and intensity modulated radiotherapy for the treatment of prostate and pelvic nodes
    Jaap Vaarkamp
    Joint Department of Physics, Royal Marsden NHS Trust and Institute of Cancer Research, Sutton, Surrey, UK
    Radiother Oncol 73:65-72. 2004
    ..We investigated whether this concave dose distribution can be produced using simplified forward planned multi segment radiotherapy (MSRT)...
  35. ncbi request reprint Medium-term outcomes of active surveillance for localised prostate cancer
    Elizabeth D Selvadurai
    The Royal Marsden Hospital, Sutton, Surrey, UK The Institute of Cancer Research, Sutton, Surrey, UK
    Eur Urol 64:981-7. 2013
    ..Active surveillance (AS) aims to allow men with favourable-risk, localised prostate cancer to avoid unnecessary treatment...
  36. pmc Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array
    Rosalind A Eeles
    The Institute of Cancer Research, Sutton, UK
    Nat Genet 45:385-91, 391e1-2. 2013
    ..7-fold higher risk than the average of the population being profiled. These results will facilitate population risk stratification for clinical studies...
  37. ncbi request reprint The impact of introducing intensity modulated radiotherapy into routine clinical practice
    Elizabeth A Miles
    Radiotherapy Department, Royal Marsden NHS Foundation Trust, London and Sutton, UK
    Radiother Oncol 77:241-6. 2005
    ..Treatment delivery was dynamic using a single-phase technique. Concerns were raised regarding increased clinical workload due to introduction of new technology. The potential increased use of resources was assessed...
  38. ncbi request reprint Long-term effects of a short course of neoadjuvant luteinizing hormone-releasing hormone analogue and radical radiotherapy on the hormonal profile in patients with localized prostate cancer
    Vedang Murthy
    Academic Unit of Radiotherapy and Oncology, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton, Surrey, UK
    BJU Int 99:1380-2. 2007
    ....
  39. ncbi request reprint Use of artificial neural networks to predict biological outcomes for patients receiving radical radiotherapy of the prostate
    Sarah L Gulliford
    Joint Department of Physics, Institute of Cancer Research and Royal Marsden NHS Trust, Sutton, Surrey SM2 5PT, UK
    Radiother Oncol 71:3-12. 2004
    ..One of the advantages of this method is that there is no need for a priori information regarding the relationship between the data being correlated...
  40. ncbi request reprint The utility of lactate dehydrogenase in the follow-up of testicular germ cell tumours
    Ramachandran Venkitaraman
    Academic Urology Unit, Institute of Cancer Research, Royal Marsden Hospital, Downs Road, Sutton, Surrey, UK
    BJU Int 100:30-2. 2007
    ....
  41. doi request reprint Additional therapy for high-risk prostate cancer treated with surgery: what is the evidence?
    Scott C Morgan
    Honorary Clinical Research Fellow, Academic Urology Unit, Institute of Cancer Research, Royal Marsden Hospital, Downs Road, Sutton, Surrey, SM2 5PT, UK
    Expert Rev Anticancer Ther 9:939-51. 2009
    ..Among these, only adjuvant radiotherapy has been shown to prolong survival after surgery, and the recently published evidence for this benefit will be discussed in detail...
  42. ncbi request reprint Tumour staging using magnetic resonance imaging in clinically localised prostate cancer: relationship to biochemical outcome after neo-adjuvant androgen deprivation and radical radiotherapy
    A S N Jackson
    The Academic Department of Radiotherapy, Royal Marsden Hospital, Sutton, Surrey, UK
    Clin Oncol (R Coll Radiol) 17:167-71. 2005
    ..To evaluate the prognostic significance of magnetic resonance imaging (MRI) tumour stage in clinically localised prostate cancer...
  43. ncbi request reprint Evaluating the effect of reducing the high-dose volume on the toxicity of radiotherapy in the treatment of bladder cancer
    S A Mangar
    Academic Radiotherapy, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK
    Clin Oncol (R Coll Radiol) 18:466-73. 2006
    ..The aims of this study were to establish the efficacy and compare the late toxicity between (1) a two-phase technique limiting the high-dose area and (2) a conventional single-phase radiotherapy to the whole bladder...
  44. ncbi request reprint Management of early prostate cancer
    A Horwich
    Department of Clinical Oncology Academic Unit, Royal Marsden Hospital, Sutton, UK
    Ann Oncol 13:83-7. 2002
  45. pmc Pre-treatment nomogram for biochemical control after neoadjuvant androgen deprivation and radical radiotherapy for clinically localised prostate cancer
    C C Parker
    Academic Department of Radiotherapy and Oncology, The Royal Marsden NHS Trust and Institute of Cancer Research, Downs Road, Sutton, Surrey SM2 5PT, UK
    Br J Cancer 86:686-91. 2002
    ..The nomogram illustrates the results of multivariate analysis in a visually-striking way, and facilitates comparisons with other treatment methods...
  46. pmc A medical research council randomized trial of single agent carboplatin versus etoposide and cisplatin for advanced metastatic seminoma. MRC Testicular Tumour Working Party
    A Horwich
    Radiotherapy Unit, Royal Marsden Hospital, Downs Rd, Sutton, Surrey, UK
    Br J Cancer 83:1623-9. 2000
    ..Standard initial chemotherapy for advanced seminoma should be based on cisplatin combinations and the role of carboplatin awaits the outcome of further studies...
  47. ncbi request reprint Correlations between dose-surface histograms and the incidence of long-term rectal bleeding following conformal or conventional radiotherapy treatment of prostate cancer
    J D Fenwick
    Joint Department of Physics, Institute of Cancer Research and the Royal Marsden NHS Trust, Downs Road, Sutton, Surrey, UK
    Int J Radiat Oncol Biol Phys 49:473-80. 2001
    ..002) than that among those treated conventionally. Here the relationship between rectal dose distributions and incidences of bleeding is assessed...
  48. ncbi request reprint Combination carboplatin and radiotherapy in the management of stage II testicular seminoma: comparison with radiotherapy treatment alone
    H Patterson
    Academic Radiotherapy Unit, Institute of Cancer Research and the Royal Marsden NHS Trust, 15 Cotswold Road, Belmont, Sutton, SM2 5NG, Surrey, UK
    Radiother Oncol 59:5-11. 2001
    ..Confirmation would require a phase III randomized comparison...
  49. ncbi request reprint Potential improvements in the therapeutic ratio of prostate cancer irradiation: dose escalation of pathologically identified tumour nodules using intensity modulated radiotherapy
    C M Nutting
    Department of Radiotherapy, Institute of Cancer Research and Royal Marsden NHS Trust, Sutton, SM2 5PT, UK
    Br J Radiol 75:151-61. 2002
    ..Improvements in prostate imaging and prostate immobilization are required before clinical implementation would be possible. Clinical trials are required to confirm the clinical benefits of these improved dose distributions...
  50. pmc HPC2/ELAC2 polymorphisms and prostate cancer risk: analysis by age of onset of disease
    J C Meitz
    Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK
    Br J Cancer 87:905-8. 2002
    ..50, 95% CI 0.79-2.85) or to patients diagnosed >55 years (OR=1.27, 95% CI 0.59-2.74). We conclude that any association between the Thr541 variant and prostate cancer is likely to be weak...
  51. doi request reprint Coplanar intensity-modulated radiotherapy class solution for patients with prostate cancer with bilateral hip prostheses with and without nodal involvement
    Young K Lee
    Joint Department of Physics, The Royal Marsden NHS Foundation Trust, Sutton, Surrey SM2 5PT, UK
    Med Dosim 38:165-70. 2013
    ..We describe an IMRT solution for patients with bilateral hip prostheses of varying size and shape, requiring either localized or whole pelvic radiotherapy for prostate cancer...
  52. ncbi request reprint Cranial nerve palsies in metastatic prostate cancer--results of base of skull radiotherapy
    Joe M O'Sullivan
    Academic Unit of Radiotherapy and Clinical Oncology, Institute of Cancer Research Royal Marsden Hospital, Sutton, Surrey SM2 5PT, UK
    Radiother Oncol 70:87-90. 2004
    ..Sixteen patients (50%; 95% CI, 34-66%) had a useful response to therapy. The median survival post-therapy was 3 months...
  53. ncbi request reprint A comparison of CT- and ultrasound-based imaging to localize the prostate for external beam radiotherapy
    Helen A McNair
    Department of Radiotherapy, Royal Marsden NHS Foundation Trust, Sutton, United Kingdom
    Int J Radiat Oncol Biol Phys 65:678-87. 2006
    ..This study assesses the accuracy of NOMOS B-mode acquisition and targeting system (BAT) compared with computed tomography (CT) in localizing the prostate...
  54. ncbi request reprint A Monte-Carlo method for interface dosimetry of beta emitters
    Francesca M Buffa
    Joint Department of Physics, Institute of Cancer Research, University of London, UK
    Cancer Biother Radiopharm 18:463-71. 2003
    ..The BSDF was found to be highly dependent on interface geometry and scoring volume; thus it is vital that BSDFs are used only in geometry conditions that are similar to those in which they were originally produced...
  55. ncbi request reprint A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial)
    David P Dearnaley
    Institute of Cancer Research and Royal Marsden Hospital, Sutton, UK
    J Natl Cancer Inst 95:1300-11. 2003
    ....
  56. pmc Prospective study of factors predicting adherence to medical advice in men with testicular cancer
    Clare Moynihan
    Academic Radiotherapy Unit, The Institute of Cancer Research and Department of Clinical Research Development, Royal Marsden National Health Service Foundation Trust, Sutton, Surrey, United Kingdom
    J Clin Oncol 27:2144-50. 2009
    ..The nonadherence end point (nonattender) was two failures to attend an outpatient appointment at least 1 month apart, despite a written reminder...
  57. ncbi request reprint Tumor dosimetry on SPECT (186)Re-HEDP scans: variations in the results from the reconstruction methods used
    Antigoni Divoli
    Joint Department of Physics, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sulton, Surrey, UK
    Cancer Biother Radiopharm 22:121-4. 2007
    ..In conclusion, the need for a standardization of the methodology used for the calculations is emphasized by this work, especially when comparisons between patients and different centers are of interest...
  58. ncbi request reprint Potential role of intensity-modulated radiotherapy in the treatment of tumors of the maxillary sinus
    E J Adams
    Joint Department of Physics, Institute of Cancer Research and the Royal Marsden NHS Trust, Sutton, Surrey, UK
    Int J Radiat Oncol Biol Phys 51:579-88. 2001
    ....
  59. ncbi request reprint Cardiovascular disease as a long-term complication of treatment for testicular cancer
    R A Huddart
    Academic Unit of Radiotherapy and Oncology, Royal Marsden NHS Trust and Institute of Cancer Research, Downs Rd, Sutton, Surrey SM2 5PT, United Kingdom
    J Clin Oncol 21:1513-23. 2003
    ..To assess the risk of cardiovascular morbidity and cardiac risk factors in long-term survivors of testicular cancer according to treatment received...
  60. ncbi request reprint Improvements in target coverage and reduced spinal cord irradiation using intensity-modulated radiotherapy (IMRT) in patients with carcinoma of the thyroid gland
    C M Nutting
    Academic Department of Radiotherapy, Institute of Cancer Research, Surrey, SM2 5PT, Sutton, UK
    Radiother Oncol 60:173-80. 2001
    ..A simultaneous integrated boost technique with five equispaced fields produced the best dose distribution. IMRT should reduce the risk of myelopathy or may allow dose escalation in patients with thyroid cancer...
  61. ncbi request reprint Association between the GCG polymorphism of the selenium dependent GPX1 gene and the risk of young onset prostate cancer
    Z Kote-Jarai
    Section of Cancer Genetics, The Institute of Cancer Research and Royal Marsden NHS Trust, Sutton, Surrey, UK
    Prostate Cancer Prostatic Dis 5:189-92. 2002
    ..67; 95% CI: 0.97-2.87). The result of this study suggests that the GPX1 genotype is unlikely to be associated with the risk of developing prostate cancer...
  62. ncbi request reprint Association between leptin receptor gene polymorphisms and early-onset prostate cancer
    Z Kote-Jarai
    Translational Cancer Genetics, and Molecular Epidemiology, The Institute of Cancer Research, Surrey, UK
    BJU Int 92:109-12. 2003
    ....
  63. ncbi request reprint Individualization of dose prescription based on normal-tissue dose-volume and radiosensitivity data
    B Sanchez-Nieto
    Joint Department of Physics, Institute of Cancer Research and the Royal Marsden NHS Trust, Sutton, Surrey, UK
    Int J Radiat Oncol Biol Phys 49:487-99. 2001
    ..The aim of this paper is to illustrate the potential gain in tumor control probability (TCP) of prostate cancer patients by individualizing the prescription dose according to both normal-tissue (N-T) dose-volume and radiosensitivity data...
  64. ncbi request reprint Optimization of coplanar six-field techniques for conformal radiotherapy of the prostate
    J L Bedford
    Joint Department of Physics, Institute of Cancer Research and Royal Marsden NHS Trust, Surrey, United Kingdom
    Int J Radiat Oncol Biol Phys 46:231-8. 2000
    ..To determine the optimal coplanar treatment technique for six-field conformal radiotherapy of prostate only (PO) or prostate plus seminal vesicles (PSV)...
  65. ncbi request reprint A comparison of conformal and intensity-modulated techniques for oesophageal radiotherapy
    C M Nutting
    Academic Department of Radiotherapy, The Institute of Cancer Research and The Royal Marsden NHS Trust, Downs Road, Sutton, SM2 5PT, Surrey, UK
    Radiother Oncol 61:157-63. 2001
    ..Thus, IMRT with a few carefully chosen field directions may lead to a modest reduction in pneumonitis, or allow tumour dose escalation within the currently accepted lung toxicity...
  66. ncbi request reprint Evaluation of the optimal co-planar field arrangement for use in the boost phase of dose escalated conformal radiotherapy for localized prostate cancer
    V S Khoo
    The Academic Unit of Radiotherapy and Oncology, The Institute of Cancer Research and The Royal Marsden NHS Trust, Sutton, Surrey, UK
    Br J Radiol 74:177-82. 2001
    ....
  67. ncbi request reprint IMRT clinical implementation: prostate and pelvic node irradiation using Helios and a 120-leaf multileaf collimator
    C H Clark
    Joint Department of Physics, The Royal Marsden NHS Trust, Fulham Road, London SW3 6JJ, United Kingdom
    J Appl Clin Med Phys 3:273-84. 2002
    ..Following the results of this commissioning and implementation study, we have started to treat men with a target Volume including the prostate and pelvic nodes using Helios optimized dynamic IMRT delivery in a dose escalation protocol...
  68. pmc Fertility, gonadal and sexual function in survivors of testicular cancer
    R A Huddart
    Academic Unit of Radiotherapy and Oncology, Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Downs Road, Sutton, Surrey SM2 5PT, UK
    Br J Cancer 93:200-7. 2005
    ..Most patients retain their fertility, but the risk of infertility is likely to be increased by chemotherapy. Screening for gonadal dysfunction should be considered in the follow-up of testicular cancer survivors...
  69. ncbi request reprint Relationship between glutathione S-transferase M1, P1 and T1 polymorphisms and early onset prostate cancer
    Z Kote-Jarai
    Section of Cancer Genetics, The Institute of Cancer Research and Royal Marsden NHS Trust, Sutton, Surrey, UK
    Pharmacogenetics 11:325-30. 2001
    ..We also found that carrying more than one putative high-risk allele in the carcinogen metabolizing GST family was associated with an elevated risk for early onset prostate cancer (OR 2.48, 95% FCI 1.22-5.04, Ptrend = 0.017)...
  70. ncbi request reprint Intensive induction chemotherapy with CBOP/BEP in patients with poor prognosis germ cell tumors
    J A Christian
    Academic Department of Radiotherapy and Oncology, Royal Marsden Hospital, Sutton, Surrey, United Kingdom
    J Clin Oncol 21:871-7. 2003
    ..This study assesses the outcome of patients with poor-prognosis nonseminomatous germ cell tumors (NSGCT) treated with CBOP/BEP...
  71. ncbi request reprint Radical radiotherapy for prostate cancer
    C C Parker
    Academic Radiotherapy, Institute of Cancer Research, Royal Marsden Hospital, Surrey SM2 5PT, UK
    Cancer Treat Rev 29:161-9. 2003
    ..Finally, future developments will be described, including hypofractionation and dose individualisation, which have the potential to further improve the outcome of external beam radiotherapy for prostate cancer...
  72. ncbi request reprint Microbiota and radiation-induced bowel toxicity: lessons from inflammatory bowel disease for the radiation oncologist
    Miguel R Ferreira
    Institute of Cancer Research, London, UK Royal Marsden NHS Foundation Trust, London, UK Instituto Gulbenkian Ciencia, Oeiras, Portugal Electronic address
    Lancet Oncol 15:e139-47. 2014
    ....
  73. ncbi request reprint Distortion-corrected T2 weighted MRI: a novel approach to prostate radiotherapy planning
    A S N Jackson
    Academic Department of Radiotherapy and Oncology, Royal Marsden Hospital and Institute of Cancer Research, Downs Rd, Sutton SM2 5PT, UK
    Br J Radiol 80:926-33. 2007
    ..This leads to a lower predicted proportion of the rectum, in particular the lower rectum (anal canal), treated to a given dose than with CT...
  74. doi request reprint Dynamic contrast-enhanced MRI for prostate cancer localization
    A S N Jackson
    Academic Department of Radiotherapy and Oncology, Royal Marsden NHS Foundation Trust and Institute of Cancer Research, Sutton, UK
    Br J Radiol 82:148-56. 2009
    ..006) and similarly specific (85% vs 81%; p = 0.593). The superior sensitivity of DCE-MRI compared with T2W images, together with its high specificity, is arguably sufficient for its use in guiding radiotherapy boosts in prostate cancer...
  75. ncbi request reprint Optimisation of radiotherapy for carcinoma of the parotid gland: a comparison of conventional, three-dimensional conformal, and intensity-modulated techniques
    C M Nutting
    Department of Radiotherapy, Institute of Cancer Research and Royal Marsden NHS Trust, Downs Road, Surrey, Sutton, UK
    Radiother Oncol 60:163-72. 2001
    ..Clinical trials are required to confirm the clinical benefits of these improved dose distributions...
  76. ncbi request reprint Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours
    J M O'Sullivan
    Academic Unit of Radiotherapy and Clinical Oncology, The Institute of Cancer Research, Royal Marsden NHS Trust, Sutton, UK
    Ann Oncol 14:91-6. 2003
    ..Postulated risk factors include cumulative bleomycin dose, reduced glomerular filtration rate (GFR), raised creatinine, older age and supplemental oxygen exposure...
  77. pmc High activity Rhenium-186 HEDP with autologous peripheral blood stem cell rescue: a phase I study in progressive hormone refractory prostate cancer metastatic to bone
    J M O'Sullivan
    Unit of Academic Radiotherapy and Clinical Oncology, Royal Marsden NHS Trust, Sutton, Surrey SM2 5PT, UK
    Br J Cancer 86:1715-20. 2002
    ..The main toxicity is thrombocytopaenia, which is short lasting. A statistically significant activity/prostate specific antigen response was seen. We have now commenced a Phase II trial to further evaluate response rates...
  78. ncbi request reprint Clinical implementation of dynamic and step-and-shoot IMRT to treat prostate cancer with high risk of pelvic lymph node involvement
    Elizabeth J Adams
    Joint Department of Physics, The Royal Marsden NHS Trust, Downs Road, Sutton, Surrey SM2 5PT, UK
    Radiother Oncol 70:1-10. 2004
    ..This paper describes the clinical implementation of these two techniques, and presents results from the first 14 patients treated in a clinical setting (nine dynamic, five step-and-shoot)...
  79. ncbi request reprint A model-based method for the prediction of whole-body absorbed dose and bone marrow toxicity for 186Re-HEDP treatment of skeletal metastases from prostate cancer
    Francesca M Buffa
    Institute of Cancer Research, London, UK
    Eur J Nucl Med Mol Imaging 30:1114-24. 2003
    ....
  80. ncbi request reprint Prostate cancer--the Royal Marsden conformal experience
    Christopher M Nutting
    Academic Unit of Radiotherapy and Oncology, Institute of Cancer Research, Royal Marsden NHS Trust, Sutton, UK
    Front Radiat Ther Oncol 37:196-9. 2002
  81. pmc Two percent of men with early-onset prostate cancer harbor germline mutations in the BRCA2 gene
    Stephen M Edwards
    Translational Cancer Genetics Team, Institute of Cancer Research, Sutton, Surrey, United Kingdom
    Am J Hum Genet 72:1-12. 2003
    ..These results confirm that BRCA2 is a high-risk prostate-cancer-susceptibility gene and have potential implications for the management of early-onset prostate cancer, in both patients and their relatives...
  82. doi request reprint Intensity-modulated radiotherapy allows escalation of the radiation dose to the pelvic lymph nodes in patients with locally advanced prostate cancer: preliminary results of a phase I dose escalation study
    T Guerrero Urbano
    Academic Unit and Department of Radiotherapy, Institute of Cancer Research and Royal Marsden Hospital, Sutton, UK
    Clin Oncol (R Coll Radiol) 22:236-44. 2010
    ..We report the preliminary results of a dose escalation study using intensity-modulated radiotherapy...
  83. ncbi request reprint Broadening the criteria for avoiding staging bone scans in prostate cancer: a retrospective study of patients at the Royal Marsden Hospital
    J M O'Sullivan
    Academic Unit of Radiotherapy and Clinical Oncology, Institute of Cancer Research Royal Marsden Hospital, Sutton, Surrey, UK
    BJU Int 92:685-9. 2003
    ....
  84. ncbi request reprint Distribution of lymph nodes in men with prostatic adenocarcinoma and lymphadenopathy at presentation: a retrospective radiological review and implications for prostate and pelvis radiotherapy
    A S N Jackson
    Academic Department of Radiotherapy and Oncology, Royal Marsden Hospital and Institute of Cancer Research, Sutton, UK
    Clin Oncol (R Coll Radiol) 18:109-16. 2006
    ..This will help to define which nodal groups should be treated during the pelvic radiotherapy of patients with less advanced disease...
  85. ncbi request reprint Recovery of serum testosterone, LH and FSH levels following neoadjuvant hormone cytoreduction and radical radiotherapy in localized prostate cancer
    M Shahidi
    Academic Department of Radiotherapy and Oncology, The Royal Marsden NHS Trust, The Institute of Cancer Research, Sutton, UK
    Clin Oncol (R Coll Radiol) 13:291-5. 2001
    ..Serum testosterone levels are restored to normal levels in the majority of patients, with a compensatory increase in serum levels of LH...
  86. ncbi request reprint Additional treatment for pT3 prostate cancer: now, later or never
    David P Dearnaley
    Academic Radiotherapy, Institute of Cancer Research, Sutton, Surrey, UK
    BJU Int 100:977-9. 2007
  87. doi request reprint Multiple newly identified loci associated with prostate cancer susceptibility
    Rosalind A Eeles
    The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey, SM2 5NG, UK
    Nat Genet 40:316-21. 2008
    ..7 x 10(-29)). We confirmed previous reports of common loci associated with prostate cancer at 8q24 and 17q. Moreover, we found that three of the newly identified loci contain candidate susceptibility genes: MSMB, LMTK2 and KLK3...
  88. ncbi request reprint Whole-body magnetic resonance imaging in the detection of skeletal metastases in patients with prostate cancer
    R Venkitaraman
    Academic Uro oncology Unit, Royal Marsden Hospital, Downs Road, Sutton, Surrey, UK
    J Med Imaging Radiat Oncol 53:241-7. 2009
    ..Whole-body MRI and radionuclide bone scintigraphy have similar specificity and sensitivity and may be used as complementary investigations to detect skeletal metastases from prostate cancer...
  89. ncbi request reprint Challenges in treating patients with Down's syndrome and testicular cancer with chemotherapy and radiotherapy: The Royal Marsden experience
    S Hafeez
    Radiotherapy Department, Royal Marsden Hospital NHS Trust, Downs Road, Sutton, Surrey SM2 5PT, UK
    Clin Oncol (R Coll Radiol) 19:135-42. 2007
    ..We aimed to identify and discuss management challenges in the treatment of these patients with chemotherapy and radiotherapy and report their clinical outcome...
  90. ncbi request reprint Prospective assessment of MRI for imaging retroperitoneal metastases from testicular germ cell tumours
    S A Sohaib
    Department of Radiology, Institute of Cancer Research and Royal Marsden Hospital, Sutton, Surrey, UK
    Clin Radiol 64:362-7. 2009
    ..To determine the sensitivity of magnetic resonance imaging (MRI) in the detection of retroperitoneal lymph nodes in patients with testicular germ cell tumours (TGCT)...
  91. ncbi request reprint Accelerated chemotherapy in the treatment of urothelial cancer
    R A Huddart
    Academic Unit of Radiotherapy and Oncology, Royal Marsden Hospital, NHS Trust, Sutton, UK
    Clin Oncol (R Coll Radiol) 13:279-83. 2001
    ..Accelerated regimens may be useful in situations were it is necessary to administer chemotherapy over a short time (e.g. as part of combined modality treatment)...
  92. ncbi request reprint An evaluation of Beam cath in the verification process for prostate cancer radiotherapy
    H A McNair
    Department of Radiotherapy, Royal Marsden NHS Trust and Institute of Cancer Research, Sutton, Surrey, UK
    Clin Oncol (R Coll Radiol) 16:138-47. 2004
    ..This study tested the feasibility of using Beam cath to enable online correction of treatment set-up in relation to the prostate position, and to assess inter-fraction and intra-fraction prostate movement...
  93. pmc Induction of transforming growth factor beta in hormonally treated human prostate cancer
    G H Muir
    Urology Unit, Institute of Cancer Research, London, UK
    Br J Cancer 69:130-4. 1994
    ..This suggests that relapse of hormonally treated prostate cancer may be associated with a failure of the epithelium to respond to stromal TGF-beta 1...
  94. pmc Allelic imbalance in familial and sporadic prostate cancer at the putative human prostate cancer susceptibility locus, HPC1. CRC/BPG UK Familial Prostate Cancer Study Collaborators. Cancer Research Campaign/British Prostate Group
    W D Dunsmuir
    CRC Section of Cancer Genetics and Molecular Carcinogenesis, Institute of Cancer Research, Sutton, Surrey, UK
    Br J Cancer 78:1430-3. 1998
    ..We conclude that the incidence of allelic imbalance at HPC1 is low in both sporadic tumours and small prostate cancer families. In this group of patients, HPC1 is unlikely to be acting as a TSG in the development of prostate cancer...
  95. pmc Evidence-based pragmatic guidelines for the follow-up of testicular cancer: optimising the detection of relapse
    N J van As
    Royal Marsden Hospital and The Institute of Cancer Research, Sutton, UK
    Br J Cancer 98:1894-902. 2008
    ..Furthermore, this should enable future trials to address specific issues around follow-up giving meaningful and useful results...
  96. ncbi request reprint Intensity-modulated radiotherapy reduces lung irradiation in patients with carcinoma of the oesophagus
    Christopher M Nutting
    Academic Department of Radiotherapy, Institute of Cancer Research, Royal Marsden NHS Trust, Sutton, UK
    Front Radiat Ther Oncol 37:128-31. 2002
  97. pmc Prostate cancer in BRCA2 germline mutation carriers is associated with poorer prognosis
    S M Edwards
    Oncogenetics team, Section of Cancer Genetics, Institute of Cancer Research, Sutton SM2 5PT, UK
    Br J Cancer 103:918-24. 2010
    ..The germline BRCA2 mutation is associated with increased prostate cancer (PrCa) risk. We have assessed survival in young PrCa cases with a germline mutation in BRCA2 and investigated loss of heterozygosity at BRCA2 in their tumours...
  98. pmc High dose BCNU chemotherapy with autologous bone marrow transplantation and full dose radiotherapy for grade IV astrocytoma
    E K Mbidde
    Section of Medicine, Institute of Cancer Research, Royal Marsden Hospital, Surrey, UK
    Br J Cancer 58:779-82. 1988
    ..Despite the suggestion of a prolongation of survival this approach is not routinely recommended and a randomised trial is probably not justified...
  99. doi request reprint Does magnetic resonance imaging of the spine have a role in the staging of prostate cancer?
    R Venkitaraman
    Academic Uro oncology Unit, Royal Marsden Hospital and Institute of Cancer Research, Sutton, Surrey, UK
    Clin Oncol (R Coll Radiol) 21:39-42. 2009
    ..The aim of this study was to compare MRI spine with radionuclide bone scan in detecting spinal metastases for staging prostate cancer patients...
  100. pmc No germline mutations in the dimerization domain of MXI1 in prostate cancer clusters. The CRC/BPG UK Familial Prostate Cancer Study Collaborators. Cancer Research Campaign/British Prostate Group
    S M Edwards
    Institute of Cancer Research, Sutton, Surrey
    Br J Cancer 76:992-1000. 1997
    ..No mutations were found in these two important coding regions and we therefore conclude that MXI1 does not make a major contribution to prostate cancer susceptibility...
  101. doi request reprint Pentoxifylline to treat radiation proctitis: a small and inconclusive randomised trial
    R Venkitaraman
    Academic Urology Unit, The Institute of Cancer Research and Royal Marsden Hospital, Sutton, UK
    Clin Oncol (R Coll Radiol) 20:288-92. 2008
    ..However, a modest benefit cannot be excluded and larger randomised placebo-controlled trials with longer durations of pentoxifylline treatment may be justified...